Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACE + Axitinib for Unresectable HCC
NCT01352728Phase 2Completed
- Sponsor
- The Chinese University of Hong Kong
- Start
- May 2011
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of axitinib in hepatocellular carcinoma (HCC), sponsored by The Chinese University of Hong Kong. Started May 2011; status: completed.
02
Drugs
axitinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT01352728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01352728.